EZH2-TTP-mTORC1轴驱动致命前列腺癌的表型可塑性和治疗脆弱性
Research square
|September 2, 2025
概括
前列腺癌的表型可塑性 (PCa) 驱动耐药性. 向性增强剂的2 (EZH2) 和PI3K/mTORC1显示出对这种致命的PCa亚型的承诺.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 表型可塑性是前列腺癌 (PCa) 治疗耐药性的关键机制.
- 关于PCa表型可塑性的驱动因素和治疗干预措施的知识有限.
- 增强性同源2 (EZH2) 之前被确定为PCa中的替代转录程序的调节剂.
研究的目的:
- 阐明前列腺癌中表型可塑性的机制.
- 研究RNA结合蛋白Tristetraprolin (TTP) 在EZH2介导的可塑性中的作用.
- 评估针对治疗耐药PCA的组合疗法.
主要方法:
- 使用缺乏Pten和Rb1的基因工程小鼠模型 (GEMMs).
- 采用多组学方法来分析分子变化.
- 评估了EZH2和PI3K/mTORC1联合化学抑制的疗效.
主要成果:
- EZH2 调节了依赖于三甲 (TTP) 的多系细胞状态.
- 通过TTP调解RNA稳定性和翻译激活.
- 在老鼠和人类模型中,联合抑制EZH2和PI3K/mTORC1显示出优异的抗瘤活性.
- 这种组合疗法在与割或恩扎胺一起使用时最有效.
结论:
- 致死性PCa的表型可塑性取决于EZH2,TTP和mTORC1信号之间的协调.
- 这种协调代表了治疗耐药PCA的新型治疗依赖性.
- 针对EZH2和PI3K/mTORC1的组合治疗提供了对致命前列腺癌的有希望的策略.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.9K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
261
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
